Axikin Pharmaceuticals
Small molecule therapeutics for respiratory and autoimmune diseases
About Axikin Pharmaceuticals
Axikin Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing and commercializing small molecule therapeutics. The company targeted severe respiratory, inflammatory, and autoimmune diseases such as asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
Founded in 2008 by Kevin B. Bacon, Ph.D., Axikin was established as a spin-out from Actimis Pharmaceuticals. This occurred after Actimis' main program was acquired by Boehringer Ingelheim. The new entity retained key scientific staff and several preclinical programs from its predecessor, which originated from Bayer Yakuhin Ltd.'s respiratory research in Japan. The company was headquartered in San Diego, California. Dr. Bacon, who founded Actimis, served as Axikin's President and Chief Scientific Officer, while Dr. Peter C. M. McWilliams of Sanderling Ventures was the acting CEO.
The company's business model was centered on advancing its drug pipeline through preclinical and clinical stages, with the ultimate goal of partnering with larger pharmaceutical companies for late-stage development and commercialization. Axikin's lead candidate was AXP1275, an orally available allosteric modulator targeting the CCR3 chemokine receptor, which is known to be up-regulated in various allergic diseases. Axikin secured initial Series A funding of $3 million in January 2009, led by Sanderling Ventures and Mitsui & Co. Venture Partners, eventually raising a total of approximately $11.6 million to $12.5 million over several funding rounds. Despite its efforts, the company ceased operations around November 2017.
Source: Dealroom company dataNews
Open roles
Axikin Pharmaceuticals in the San Diego ecosystem
The Axikin Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Sanderling Ventures
Mitsui Global Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Axikin Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Axikin Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

